Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome
Author: Goldwater, P.
Citation: Expert Review of Anti-infective Therapy, 2007; 5(4):653-663
Publisher: Future Drugs Ltd.
Issue Date: 2007
ISSN: 1478-7210
Statement of
Goldwater P.N.
Abstract: Over a quarter century after the discovery of verocytotoxin and the first report by Karmali and colleagues of cases of postdiarrheal hemolytic uremic syndrome (HUS) caused by verotoxigenic Escherichia coli (VTEC), otherwise known as Shiga-toxigenic E. coli (STEC), successful treatment of these infections has remained elusive. This is because the pathological insult producing the clinical picture of HUS occurs early in the disease process and curtails quickly, making treatment intervention a largely vain hope. Nevertheless, understanding of the pathogenesis of HUS has expanded and, as a result, we can expect a future breakthrough in the treatment of this life-threatening condition. This review examines the pathogenesis of HUS and explores targets for treatment, including the reasons why certain therapies have failed and why future therapies could be successful. This review also examines the status of vaccine development in prevention of VTEC/STEC disease.
Keywords: Animals
Escherichia coli O157
Escherichia coli Infections
Hemolytic-Uremic Syndrome
Virulence Factors
Escherichia coli Vaccines
Antibodies, Monoclonal
Anti-Bacterial Agents
Risk Factors
Genetic Therapy
DOI: 10.1586/14787210.5.4.653
Description (link):
Published version:
Appears in Collections:Aurora harvest
Paediatrics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.